Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 1
2004 3
2005 5
2006 11
2007 8
2008 10
2009 19
2010 21
2011 25
2012 31
2013 34
2014 34
2015 30
2016 31
2017 36
2018 42
2019 34
2020 43
2021 51
2022 34
2023 26
2024 33
2025 28

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

489 results

Results by year

Filters applied: . Clear all
Page 1
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer.
Kopetz S, Grothey A, Yaeger R, Van Cutsem E, Desai J, Yoshino T, Wasan H, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Pfeiffer P, Orlov S, Lonardi S, Elez E, Kim TW, Schellens JHM, Guo C, Krishnan A, Dekervel J, Morris V, Calvo Ferrandiz A, Tarpgaard LS, Braun M, Gollerkeri A, Keir C, Maharry K, Pickard M, Christy-Bittel J, Anderson L, Sandor V, Tabernero J. Kopetz S, et al. Among authors: hong ys. N Engl J Med. 2019 Oct 24;381(17):1632-1643. doi: 10.1056/NEJMoa1908075. Epub 2019 Sep 30. N Engl J Med. 2019. PMID: 31566309 Clinical Trial.
Angiogenesis in Chronic Inflammatory Skin Disorders.
Lee HJ, Hong YJ, Kim M. Lee HJ, et al. Among authors: hong yj. Int J Mol Sci. 2021 Nov 7;22(21):12035. doi: 10.3390/ijms222112035. Int J Mol Sci. 2021. PMID: 34769465 Free PMC article. Review.
Encorafenib Plus Cetuximab as a New Standard of Care for Previously Treated BRAF V600E-Mutant Metastatic Colorectal Cancer: Updated Survival Results and Subgroup Analyses from the BEACON Study.
Tabernero J, Grothey A, Van Cutsem E, Yaeger R, Wasan H, Yoshino T, Desai J, Ciardiello F, Loupakis F, Hong YS, Steeghs N, Guren TK, Arkenau HT, Garcia-Alfonso P, Elez E, Gollerkeri A, Maharry K, Christy-Bittel J, Kopetz S. Tabernero J, et al. Among authors: hong ys. J Clin Oncol. 2021 Feb 1;39(4):273-284. doi: 10.1200/JCO.20.02088. J Clin Oncol. 2021. PMID: 33503393 Free PMC article. Clinical Trial.
3D printing for oral drug delivery: a new tool to customize drug delivery.
Pandey M, Choudhury H, Fern JLC, Kee ATK, Kou J, Jing JLJ, Her HC, Yong HS, Ming HC, Bhattamisra SK, Gorain B. Pandey M, et al. Among authors: yong hs. Drug Deliv Transl Res. 2020 Aug;10(4):986-1001. doi: 10.1007/s13346-020-00737-0. Drug Deliv Transl Res. 2020. PMID: 32207070 Review.
National Brain Tumour Registry of China (NBTRC) statistical report of primary brain tumours diagnosed in China in years 2019-2020.
Xiao D, Yan C, Li D, Xi T, Liu X, Zhu D, Huang G, Xu J, He Z, Wu A, Ma C, Long J, Shu K, Ji H, Wang N, Chen G, Yang J, Ma H, Li Z, Sun X, Qu Y, Liu Z, Jiang X, Tian C, Ni S, Zhan R, Chen L, Ge M, Wang M, Jiang X, Guo G, Han Z, Zhang C, Zhang T, Dou C, Chu L, Wang P, Shao J, Wu X, Yu J, Wang Y, Wu N, Zhang R, Zhang M, Hong Y, Gao J, Li Y, Pan Y, Zhao B, Ji N, Shan G, Patel CB, Jia W, Zhang L. Xiao D, et al. Among authors: hong y. Lancet Reg Health West Pac. 2023 Feb 21;34:100715. doi: 10.1016/j.lanwpc.2023.100715. eCollection 2023 May. Lancet Reg Health West Pac. 2023. PMID: 37283963 Free PMC article.
ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma.
Yen I, Shanahan F, Lee J, Hong YS, Shin SJ, Moore AR, Sudhamsu J, Chang MT, Bae I, Dela Cruz D, Hunsaker T, Klijn C, Liau NPD, Lin E, Martin SE, Modrusan Z, Piskol R, Segal E, Venkatanarayan A, Ye X, Yin J, Zhang L, Kim JS, Lim HS, Kim KP, Kim YJ, Han HS, Lee SJ, Kim ST, Jung M, Hong YH, Noh YS, Choi M, Han O, Nowicka M, Srinivasan S, Yan Y, Kim TW, Malek S. Yen I, et al. Among authors: hong ys. Nature. 2021 Jun;594(7863):418-423. doi: 10.1038/s41586-021-03515-1. Epub 2021 May 5. Nature. 2021. PMID: 33953400 Clinical Trial.
Olaparib with or without bevacizumab versus bevacizumab plus a fluoropyrimidine as maintenance therapy in advanced colorectal cancer: The randomized phase 3 LYNK-003 study.
Takashima A, García-Alfonso P, Manneh R, Beşen AA, Hong YS, Cuyle PJ, Yanez P, Burge M, Yoshino T, Kim TW, Cui K, Li C, Jain R, Adelberg D, Taieb J. Takashima A, et al. Among authors: hong ys. Eur J Cancer. 2024 Jul;205:114036. doi: 10.1016/j.ejca.2024.114036. Epub 2024 Mar 21. Eur J Cancer. 2024. PMID: 38749110 Free article. Clinical Trial.
489 results